Denali reports Q2 net loss $58.8M; collaboration revenue $52.5M on $40M Sanofi milestone

Denali Therapeutics Inc.

2022-Q2 EPS reported -$1.01 revenue$94,621,000

Net loss $58.8M vs $60.7M year ago; cash and securities $1.16B as of June 30, 2022.
Collaboration revenue $52.5M, up from $22.9M, driven by $40M milestone from Sanofi (RIPK1) and $12M from Takeda (TREM2 CTA).
R&D expenses $92.7M (+41% YoY) due to clinical progress in ETV:IDS, LRRK2, and TV platform programs.
Phase 1 dosing started for DNL919 (ATV:TREM2) in Alzheimer’s; Phase 2b LUMA study for BIIB122 in Parkinson’s underway.
Initiated Phase 2/3 COMPASS study for DNL310 in Hunter syndrome; data presentations planned for H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.